African Pioneer Share Discussion Threads

[currypasty] 15/3/2006 07:42

15 March 2006


Ascribe plc ("Ascribe" or "the Group")

Ascribe acquires Patient Administration System ("PAS") supplier Barwick Systems
Limited ("Barwick") for #2.0 million.

Ascribe (AIM:ASP), the health IT Group, announces today an important strategic
move and expansion of their offering with the acquisition of Barwick Systems, a
supplier of pan hospital Patient Administrations Systems "PAS". Barwick Systems
provides software to 13 hospitals within the UK National Health Service
including software to private hospitals in the UK, many of which also use
Ascribe's Pharmacy or Accident & Emergency systems.

The total consideration of #2.0 million is to be satisfied by cash. The
acquisition will be earnings enhancing in the first year.

This acquisition enables Ascribe to offer a complete administration and clinical
system to a hospital for the first time. Barwick has recently signed a contract
to replace a legacy PAS system at an NHS Trust where the National Programme has
been unable to deliver. Together with the software from Ascribe a total solution
can be offered to meet all the needs facing clinicians and managers today.

In the year ended 31 March 2005, Barwick Systems made a profit before tax of
#191,444 on a turnover of #706,595. Barwick is growing well and together with
the cross selling opportunities, this acquisition will offer significant
opportunities in the coming years.

Commenting, Stephen Critchlow, Executive Chairman of Ascribe plc, said: "This
acquisition is immediately earnings enhancing, but more importantly is a
strategic move to place Ascribe in the Patient Administration System market.
Patient information systems are a crucial component of the Government's
healthcare agenda. The Ascribe offering will now enable Trusts to integrate
their departmental systems with their administrative systems and also have a
system that can be compliant with all National Initiatives. Ascribe is now well
placed to meet all the IT needs of our Healthcare customers.

[ltinvestor] 09/3/2006 12:10

Interims 15th March.Looking good.

[currypasty] 09/3/2006 09:45

she's off today !!

[currypasty] 23/2/2006 08:53

RNS Number:8236Y
Ascribe plc
23 February 2006


Ascribe plc (the "Company")

Holding in Company

The Company was informed on 21 February 2006 by Universities Superannuation
Scheme Limited ("USS") that USS have increased their interest to 3,984,909
ordinary shares of 1p each in the Company ("Ordinary Shares"), representing 3.72
per cent. of the Company's current issued ordinary share capital.

23 February 2006

[currypasty] 20/2/2006 08:58

moving up today

[typo56] 17/2/2006 21:02

Looks like a major holding may have got placed today. Remember the TRX connection.

[currypasty] 30/1/2006 15:29

2 million share cross... that should trigger a holding rns



edit...


RNS Number:7805X
Ascribe plc
01 February 2006


Ascribe plc (the "Company")


Holding in Company



The Company was informed on 1 February 2006 by Artemis Investment Management
Limited ("Artemis") that Artemis and certain of its subsidiaries have increased
their interest to 10,943,135 ordinary shares of 1p each in the Company
("Ordinary Shares"), representing 10.23 per cent. of the Company's current
issued ordinary share capital.

[ltinvestor] 09/11/2005 14:04

I thought that you were a long term investor!

[currypasty] 09/11/2005 11:05

9 November 2005



Grant of Options

On 26 October 2005 the Board of Ascribe plc, the health IT group focusing on
medicines management, granted 2,000,000 options over ordinary shares of 1p each
("Ordinary Shares") to the Company's Chief Executive, Graham Lewis, at an option
price of 36p per Ordinary Share.


The number of Ordinary Shares over which options are held by Graham Lewis
following this notification is 2,000,000. No consideration was paid for the
grant of these options. The period during which these options are exercisable is
26 October 2008 to 26 October 2015.




crikey... i hope to be able to cash my shares in before 2015 !!

[currypasty] 02/11/2005 09:31

consolidated at 36, looking for next move up IMO

[currypasty] 26/10/2005 08:15

26th October 2005


Ascribe plc: Annual General Meeting

Board appointments and trading update

Ascribe plc, the health IT group focusing on medicines management, will today
announce at its Annual General Meeting the following of board appointments and
the strengthening of its management team.

Stephen Critchlow, current Chief Executive is appointed as Executive Chairman
and Graham Lewis joins Ascribe as Chief Executive Officer, with immediate
affect.

Graham Lewis, aged 48, has worked in the healthcare industry for over 27 years.
After training as an engineer with GEC Medical he joined Siemens in 1979, where
his role involved business development within the burgeoning PFI market and
responsibility for establishing Siemens Healthcare Services. In 1999 Graham was
appointed Chief Executive Officer of Metier Healthcare, a joint venture between
Siemens, Bouyges and Charterhouse, from which he was then appointed Managing
Director of Siemens Healthcare Services Limited. Since 2002 Graham has been
Chief Executive of the publicly quoted interactive healthcare group, Ultrasis
plc.

Chris Moore, who was recently appointed Executive Chairman of Torex Retail plc,
will remain non-executive director but has indicated his intention to step down
from the board on Friday 16th December 2005, the first anniversary of Ascribe
plc's admission to the AIM market. He will remain a strategic consultant to the
group.

In accordance with good corporate governance, the Board of Ascribe plc will seek
to appoint another non-executive director in due course.

Ascribe also announces that the company's trading performance in the first
quarter of the financial year was in line with management expectations and that
the Directors remain confident for the year as a whole. The Group is winning new
orders in each of its three operating divisions by:

* converting additional NHS trusts to Ascribe's existing product portfolio;
* enlarging the user licenses for existing clients; and
* driving the sale of new products to new and existing customers.

The Group continues to win market share with orders to install new departmental
Pharmacy and A&E solutions with NHS Trusts. Ascribe's Substance Misuse software
has been ordered by two new customers and the sales team is addressing the
considerable interest shown in this product by other primary care clinics around
the country. In addition Ascribe's intravenous pharmacy solution and a two-way
robotic dispensing interface system has been ordered by Pharmacy customers. New
systems have been installed and launched at Calderdale & Huddersfield,
Wolverhampton and the Christie Hospitals.

Our Mental Health & Community Care division is also continuing to widen its user
base with another two major customers extending their licenses to encompass more
field-based health professionals utilising their healthcare communications
solutions. The Primary and Unscheduled Care Division has won another order for
its Symphony A&E software from a NHS Trust in the south of England.

Stephen Critchlow, Executive Chairman, Ascribe plc said:

"Ascribe's first year as a quoted company has been very successful, not only in
terms of profitability but also in developing the business into a formidable
force within the UK healthcare IT market. We are now at the next stage of
strategic positioning and corporate development, with the increased need for
greater management strength, and therefore we are delighted to welcome Graham on
board. He has a wealth of managerial and business experience from the healthcare
sector, which will prove invaluable to us in the forthcoming years.

Today's trading statement highlights the continued progress that the Group is
making in winning market share and widening the usage of Ascribe's products by
health professionals. Satisfying the market demand for solutions to improve
health is the driver to the growth that the Group is experiencing.

Chris Moore joined us to oversee the company's development into a publicly
quoted entity, a market leading company, with an excellent product strategy and
great potential in the high growth medicines management sector. With the arrival
of Graham, he remains confident that the right team is in place to drive the
group forward and build on Ascribe's success. On behalf of the Board I would
personally like to thank Chris for all his commitment and assistance during this
important phase of Ascribe's corporate development. We are pleased that we will
continue to benefit from his advice as a strategic consultant to the group."

Contacts:

Ascribe plc
Stephen Critchlow
Executive Chairman Tel: [phone]

[currypasty] 06/10/2005 07:42

Dividends

The Board has decided to recommend a progressive dividend policy that shares
some of the trading success with shareholders whilst recognising the requirement
for cash to pursue further acquisitions. The Board recommends a first and final
dividend of 0.1p per share. Subject to approval by the shareholders at the AGM
on 26 October 2005 this dividend will be paid on 27 October 2005 to shareholders
on the register at the close of business on 7 October 2005.

[currypasty] 03/10/2005 12:45

mm's must be getting short by now, there has been alot of buying, from a string of tips recently.

[currypasty] 30/9/2005 15:01

half a page spread in Investors chronical today, BUY !

[currypasty] 30/9/2005 08:46

TIPS - LARGE COMPANIES: SMITH & NEPHEW (buy), ICAP (buy), RESTAURANT GROUP
(sell); TIPS - SMALLER COMPANIES: GOLDEN PROSPECT (buy), ASCRIBE (buy), FINSBURY
FOOD (buy); TIPS - UPDATES: ITV (buy), ASCENT RESOURCES (buy), CARE (UK) (buy),
PENNON (buy), SOLITAIRE (good value)

[currypasty] 27/9/2005 12:23

RNS Number:8095R
Ascribe plc
27 September 2005


Ascribe plc (the "Company")


Holding in Company



The Company was informed on 26 September 2005 by Lloyds TSB Development Capital
Limited that it no longer has a notifiable interest in the issued ordinary share
capital of the Company.

[currypasty] 26/9/2005 12:43

Small cap values

Ascribe

More people die each year from taking wrongly prescribed medicine than in road accidents, Ascribe claims. The company has a solution. It supplies half the UK's hospitals with software to help them order medicine correctly.

This is still a young company and its strategy relies heavily on acquisitions - always risky and dealing with the NHS can be a laborious process. However, it is cash generative and is starting to supply overseas hospitals. Last year the company increased pre-tax profit from £85,000 to £1.13m.

The shares, at 35½p, trade on a forward p/e of 24. This leaves no room for error but the company is in a good market. Buy.

[wjccghcc] 23/9/2005 09:38

Results look pretty good but the valuation isn't cheap IMHO. PE of 36 dropping to 22 ain't cheap for a small software company.

[ltinvestor] 22/9/2005 10:43

It looks like LDC stake picked up by Artemis at 30p when bid was 28p so they must be very confident about tomorrows results!

[currypasty] 22/9/2005 09:52

Number:6106R
Ascribe plc
22 September 2005


Ascribe plc (the "Company")

Holding in Company

The Company was informed on 21 September 2005 by Artemis Investment Management
Limited ("Artemis") that Artemis and certain of its subsidiaries are interested
in 8,943,135 ordinary shares of 1p each in the Company ("Ordinary Shares"),
representing 8.36 per cent. of the Company's current issued ordinary share
capital.

[currypasty] 19/9/2005 21:20

could well be, 9.2 mil traded today. rns on who has sold/bought should be issued tomorrow